Collaboration and License Agreements (Tables)

3 Months Ended

Mar. 31, 2015

Collaboration and License Agreements

Schedule of revenue attributable to transactions from collaborative and license arrangements

The following table provides amounts included in our consolidated statements of operations as collaborative arrangements revenue attributable to transactions from these collaborative and license arrangements (in thousands):

	Three Months Ended
	March 31,
	2015		2014
Actavis plc	$	25,325	$	8,447
AstraZeneca AB	1,230		408
Almirall, S.A.	101		4,481
Astellas Pharma Inc.	2,276		1,269
Total collaborative arrangements revenue	$	28,932	$	14,605

Schedule of amounts recorded for commercial efforts related to LIZNESS

The following table presents the amounts recorded by the Company for commercial efforts related to LINZESS in the three months ended March 31, 2015 and 2014 (in thousands):

	Three Months Ended
	March 31,
	2015			2014
Collaborative arrangements revenue (1)(2)	$	25,137		$	8,447
Selling, general and administrative costs incurred by the Company (1)	(7,688		)	(7,999		)
The Company’s share of net profit	$	17,449		$	448

(1) Includes only collaborative arrangement revenue or selling, general and administrative costs attributable to the cost-sharing arrangement with Actavis.

(2) Includes a net profit share adjustment of approximately $1.2 million recorded during the quarter ended March 31, 2015, as described above.